Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

83.81 -8.12 (-8.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the... 
Via Benzinga
Exposures Product Safety
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Recap: Corcept Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Preview: Corcept Therapeutics
Via Benzinga
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition. 
Via Chartmill
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
Despite its growth, NASDAQ:CORT remains within the realm of affordability.
Looking for growth without the hefty price tag? Consider NASDAQ:CORT. 
Via Chartmill
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday?
Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes. 
Via Benzinga
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. 
Via Chartmill
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued. 
Via Chartmill
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading... 
Via Benzinga
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Crude Oil Down 2%; Tesla Deliveries Top Estimates
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Turns Higher; Anavex Life Sciences Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.13% to 37,739.18 while the NASDAQ fell 1.29% to 14,818.23. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Court Finds Corcept Therapeutics’ Patents Not Infringed
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.